Astex Pharmaceuticals to Present at World Epigenetics Summit on December 8th

DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that Tom Heightman, Ph.D., director, medicinal chemistry, will co-chair and present at the 2nd World Epigenetics Summit: Unlocking the Commercial and Therapeutic Potential of Epigenetics Research on December 6 to 8, 2011 in Munich.

Dr. Heightman’s presentation will occur on Dec 8th at 4:20 pm CET. He will discuss the Pyramid™ fragment-based drug discovery platform and its application towards epigenetic targets, and the current development of SGI-110, the Company’s second generation DNA hypomethylating agent. SGI-110 is a follow on to Astex Pharmaceuticals’ marketed product, Dacogen® (decitabine) for Injection, and is currently in a phase 1-2 clinical trial in myelodysplastic syndromes and acute myeloid leukemia patients. The Company is working with several cancer centers and the Stand Up to Cancer Epigenetics Dream Team on SGI-110.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.



CONTACT:

Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel: (925) 560-2810
E-mail: [email protected]
or
Alan Roemer
The Trout Group
Managing Director
Tel: (646) 378-2945
E-mail: [email protected]
or
Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel: (925) 560-2845
E-mail: [email protected]
or
Melanie Toyne-Sewell (Europe)
Rebecca Skye Dietrich (US)
College Hill
Tel: +44 20 7866 7866
Tel: (857) 241-0795
E-mail: [email protected]

KEYWORDS:   United States  Europe  North America  California  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.